Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma

Alessandra Venanzi, Andrea Marra, Gianluca Schiavoni, Sara G. Milner, Roberto Limongello, Alessia Santì, Valentina Pettirossi, Simona Ultimo, Luisa Tasselli, Alessandra Pucciari, Lorenza Falini, Sofia Sciabolacci, Maria Paola Martelli, Paolo Sportoletti, Stefano Ascari, Brunangelo Falini, and Enrico Tiacci

ABSTRACT

Clonal hematopoiesis predisposes to hematologic malignancies. However, clonal hematopoiesis is understudied in classic Hodgkin lymphoma (cHL), a mature B-cell neoplasm exhibiting the most abundant microenvironment. We analyzed clonal hematopoiesis in 40 cHL cases by sequencing microdissected tumor cells and matched normal cells from blood and/or lymph nodes. Five patients had blood and/or tissue clonal hematopoiesis. In three of five patients (all failing first-line therapy), clonal hematopoiesis spread through the tissue microenvironment extensively, and featured mutant DNMT3A R882H, KRAS G60D, and DNMT3A R882H+TET2 Q1274* in 33%, 92%, and 60% of non-neoplastic cells, respectively. In the latter case, DNMT3A/TET2-mutant clonal hematopoiesis seeded the neoplastic clone, which was infected by the Epstein–Barr virus and showed almost no other somatic mutations exome-wide. In the former case, DNMT3A-mutant clonal hematopoiesis did not originate the neoplastic clone despite dominating the blood and B-cell lineage (∼94% leukocytes; ∼96% mature blood B cells), yet led to NPM1-mutated acute myeloid leukemia 6 years after therapy for cHL. Our results expand to cHL the spectrum of hematologic malignancies associated with clonal hematopoiesis.

SIGNIFICANCE: Clonal hematopoiesis can be present in the cHL tissue, can give rise to the tumor clone, and can spread to large parts of its microenvironment. Even when massive, clonal hematopoiesis does not always give rise to the neoplastic clone of multiple myeloid and lymphoid neoplasms occurring in the same patient.
Clonal Hematopoiesis in Classic Hodgkin Lymphoma

RESULTS
Prevalence of Clonal Hematopoiesis in Patients with cHL

To assess the frequency of clonal hematopoiesis in patients with cHL, we interrogated our previous whole-exome sequencing (WES) data from non-HRS cells of 34 cHL cases, which we used as a matched normal counterpart to call somatic mutations in HRS cells (15). In particular, we reanalyzed WES data focused on protein-changing mutations upon WES (ref. 15; Fig. 1A; Supplementary Table S2).

Case 3 was an 83-year-old male, who had an EBV-positive nodular sclerosis cHL, stage IIA, and remained free from progression 64 months after doxorubicin hydrochloride, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) and salvage autologous hematopoietic stem cell transplantation (ASCT). He had a mixed cellularity cHL negative for Epstein–Barr virus (EBV) infection, in which a KRASG12D mutation massively expanded throughout reactive tissue cells (VAF = 45.9%) while being absent in HRS cells; conversely, the latter carried 57 somatic protein-changing mutations upon WES (ref. 15; Fig. 1A; Supplementary Table S2).

Case 5 was a 73-year-old male, who presented with mixed cellularity cHL, stage IIA, and was studied at relapse after six cycles of ABVD. In his tissue biopsy, the latter had 97 somatic mutations on WES (ref. 15; Fig. 1B; Supplementary Table S2). He carried a NPM1-mutated acute myeloid leukemia (AML; ref. 11).

Classical Hodgkin lymphoma (cHL) is a unique tumor entity featuring a small neoplastic clone of Hodgkin/Reed–Sternberg (HRS) cells dispersed in an exuberant supportive microenvironment largely of hematopoietic origin, with T cells representing a major component especially in the two most common histologic subtypes of this cancer (nodular sclerosis and mixed cellularity; refs. 12, 13). Recent genetic analyses of cHL focused on mutations somatically present in HRS cells but not in matched normal cells, uncovering several new mutated genes driving lymphoma cell growth and immune evasion (14–17). Clonal hematopoiesis has been detected in HSPCs harvested from 9 of 64 (14%) cHL relapsed patients of unknown age undergoing autologous transplantation (18). However, no data exist on the potential presence of clonal hematopoiesis in the microenvironmental and/or neoplastic components of cHL tissue. Here, we assessed clonal hematopoiesis frequency and tissue distribution in 40 well-characterized cHL cases largely studied at disease onset, and also describe the surprising findings on a young cHL patient with massive CHIP who developed AML following therapy for cHL.

Among the 40 patients with cHL studied in total, tissue biopsies were analyzed at onset of lymphoma in 32 cases, at relapse in 7 cases and at both time points in 1 case; for each patient with an available whole-blood sample, the latter was analyzed at the same time point as the tissue biopsy, except in the case studied both at onset and at relapse whereby blood was available only at relapse.

Median age was 35 years (range 15–83); 13 patients were >55 and 5 patients >70 years old. Clonal hematopoiesis was detected in the peripheral blood and/or cHL tissue in 5 of 40 cases (12.5%; Table 1). We note that the coverage depth of WES, which was used in the vast majority of our cases, can miss small-sized clonal hematopoiesis, and, therefore, a higher prevalence of clonal hematopoiesis might result upon deeper targeted sequencing. Clonal hematopoiesis was frequent in patients above 70 years (3/5, 60%; cases 3, 4, and 5), whereas only 2 of 35 (5.7%) patients younger than 70 years (cases 1–2) showed clonal hematopoiesis ($P = 0.009$ by Fisher exact test; Table 1), in line with the known increase of CHIP frequency with age (1–9).

Tissue Distribution of Clonal Hematopoiesis in Patients with cHL

We then dissected the distribution of clonal hematopoiesis through the cHL tissue in each of these five cases. Case 1 was notable for the development of cHL followed by AML and will be described separately in the next section.

Case 2 was a 31-year-old male, who presented with stage IVB at onset and was studied at progression following both doxorubicin hydrochloride, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) and salvage autologous hematopoietic stem cell transplantation (ASCT). He had a mixed cellularity cHL negative for Epstein–Barr virus (EBV) infection, in which a KRASG12D mutation massively expanded throughout reactive tissue cells (VAF = 45.9%) while being absent in HRS cells; conversely, the latter carried 57 somatic protein-changing mutations upon WES (ref. 15; Fig. 1A; Supplementary Table S2).

Case 3 was an 83-year-old male, who had an EBV-positive mixed cellularity cHL, stage IIb, and died of chemotherapy complications. Targeted sequencing of the onset tissue biopsy documented a likely pathogenic mutation of CBL (G375S; ref. 19) that was present at a relatively low VAF (2.5%) in reactive tissue cells and was absent in HRS cells (Supplementary Fig. S2; Supplementary Table S2).

Case 4 was an 81-year-old female. She had an EBV-negative nodular sclerosis cHL, stage IIA, and remained free from progression 64 months after doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) polychemotherapy. She carried a TET2R1274* spread considerably in reactive tissue cells (VAF = 3.2%) but not in reactive tissue cells or in HRS cells; the latter had 97 somatic mutations on WES (ref. 15; Fig. 1B; Supplementary Table S2).

Case 5 was a 73-year-old male, who presented with mixed cellularity cHL stage IIA and was studied at relapse 35 months after six cycles of ABVD. In his tissue biopsy, DNMT3ARRR822H and TET2Q1274* spread considerably in reactive tissue cells (VAF = 30% and 8.4%, respectively); however, unlike the previous cases (including case 1 also showing DNMT3ARRR822H-mutant clonal hematopoiesis; see next section), both mutations...
Table 1. Prevalence and tissue distribution of clonal hematopoiesis in patients (n = 40) with cHL

<table>
<thead>
<tr>
<th>CH present</th>
<th>Years of age</th>
<th>Pt.#</th>
<th>Time of sampling</th>
<th>Progressed after first-line chemotherapy</th>
<th>Gene mutation</th>
<th>VAF in whole blood</th>
<th>VAF in microdissected Reactive lymphoid cells</th>
<th>VAF in whole tissue section</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO (n = 35)</td>
<td>Median 35, Range 15-75</td>
<td>30</td>
<td>2nd relapse</td>
<td>YES</td>
<td>KRAS G60D</td>
<td>NA</td>
<td>45.9%</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td>83</td>
<td>Onset</td>
<td>Not evaluable</td>
<td>CBL G375S</td>
<td>NA</td>
<td>2.5%</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td>81</td>
<td>Onset</td>
<td>NO</td>
<td>TET2 N1487fs84</td>
<td>3.2%</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>YES (n = 5)</td>
<td>Onset</td>
<td>73</td>
<td>1st relapse</td>
<td>YES</td>
<td>DNMT3A R882H</td>
<td>NA</td>
<td>30%</td>
<td>43%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TET2 Q1274*</td>
<td>DNMT3A R882H</td>
<td>8.4%</td>
<td>31.1%</td>
<td>26.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>45</td>
<td>Onset</td>
<td>YES</td>
<td>DNMT3A R882H</td>
<td>47%</td>
<td>16.4%</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NPM1 W288CfsTer12</td>
<td>NA</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PTPN11 E76K</td>
<td>NA</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FLT3 ITD</td>
<td>NA</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FLT3 ITD</td>
<td>NA</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STAT6 N417Y</td>
<td>NA</td>
<td>ND</td>
<td>36.9%</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STAT6 D419H</td>
<td>NA</td>
<td>ND</td>
<td>35.7%</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SOCS1 P83Afs*25</td>
<td>NA</td>
<td>ND</td>
<td>98.6%</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CH, clonal hematopoiesis; NA, not available; ND, not detected.

*aMutant/wild-type ratio by fragment length analysis.
Figure 1. Tissue involvement by clonal hematopoiesis in cHL. A, In this EBV-negative mixed cellularity cHL (case 2), the reactive tissue microenvironment (mostly represented by T cells—not shown) belonged to clonal hematopoiesis almost entirely, as it featured a KRAS\textsubscript{G60D} mutation at a VAF of 45.9%. However, the HRS cell clone developed from a B cell not belonging to clonal hematopoiesis, after acquiring a JAK2 gain and a B2M mutation (genetic lesions typical of cHL), along with 55 additional somatic protein-changing mutations detected by WES in the HRS cell clone (ref. 15; “+55” in the HRS cell nucleus). Myeloid involvement by clonal hematopoiesis is presumptive because we did not have a blood or bone marrow sample from this patient to formally confirm it. HSC, hematopoietic stem cell. B, In EBV-negative nodular-sclerosis case 4, clonal hematopoiesis (carrying TET2\textsubscript{N1487Ifs84}, which was detected in whole-blood leukocytes and likely involved the myeloid lineage [only or mainly], did not spread through either the lymphoid HRS cell clone or its reactive tissue microenvironment. Also indicated are mutations of two genes (ITPR3 and GRM7, recurrently targeted in cHL; ref. 15) that were found in HRS cells but not in blood leukocytes of this cHL case, along with an additional 95 somatic protein-changing mutations detected by WES in the HRS cell clone (ref. 15; “+95” in the HRS cell nucleus). (continued on next page)

were carried over in the HRS cell clone, which was infected by EBV and otherwise had only three somatic mutations detected by WES (ref. 15; Fig. 1C; Supplementary Table S2). Retrospective targeted sequencing of whole sections from the formalin-fixed lymph node biopsy at cHL onset of case 5 documented the same DNMT3A\textsubscript{R882H} and TET2\textsubscript{Q1274*} mutations at 32% and 22% VAF, respectively (Table 1 and Supplementary Table S2), indicating a consistent association of microenvironmental clonal hematopoiesis with cHL pathogenesis in this patient and confirming the inability of chemotherapy to clear clonal hematopoiesis (9).

Trajectories of Clonal Hematopoiesis in a cHL Patient Sequentially Developing AML

Case 1 was a 45-year-old man diagnosed with nodular sclerosis, stage IVB cHL, negative for EBV (Fig. 2A–C). After failing polychemotherapy with ABVD, he was successfully salvaged with a second-line regimen (ifosfamide, gemcitabine,
venorelbine; IGEV) and ASCT, followed by consolidating radiotherapy. Almost 6 months after cHL diagnosis, he developed AML with clonal mutations of NPM1 and DNMT3A<sup>R882H</sup>, and subclonal PTPN11 and FLT3-ITD mutations. The bone marrow karyotype was normal and no mutations of TP53 or PPM1D were identified, in contrast to what is typically observed in therapy-related AML (Supplementary Data). Retrospective analysis of blood DNA at cHL diagnosis revealed DNMT3A<sup>R882H</sup> at high VAF (47%, i.e., ~94% of blood cells), indicating massive clonal hematopoiesis from which AML later arose after acquiring the NPM1 mutation (Fig. 2D; Table 1; Supplementary Table S2), which is typically associated with de novo AML (20).

To deconstruct DNMT3A<sup>R882H</sup> distribution through lymphopoiesis, we sequenced purified mature B and T cells from a fresh peripheral blood sample taken during remission from AML. DNMT3A<sup>R882H</sup> was observed in almost all B cells (VAF = 48%) and some T cells (VAF = 6.9%; Table 1; Supplementary Table S2). Targeted sequencing of the cHL neoplastic and nonneoplastic components microdissected from a lymph node biopsy (Supplementary Fig. S1) documented DNMT3A<sup>R882H</sup> in a considerable proportion (VAF = 16.4%) of reactive cells mostly of T-cell origin (Fig. 2C; Supplementary Fig. S1) but, surprisingly, its absence in HRS cells (Fig. 2D; Table 1; Supplementary Table S2). The latter cells carried clonal STAT6 and SOCS1 mutations typical of cHL (15).

In general, clonal hematopoiesis appeared more frequently in cases studied in the lymph node (4/15, 27%) versus the blood (2/27, 7%; cases 1 and 4 were studied in both compartments). However, this difference was not significant (Fisher exact test \( P = 0.16 \)) and could have been confounded by the significantly older age of the former versus the latter group (mean of 56 and 37 years, respectively; unpaired \( t \) test \( P = 0.003 \)).

In all three cases (1, 2, and 5) with significant clonal hematopoiesis spreading (VAF ≥ 10%) through the mostly lymphoid microenvironment, the latter was found to be polyclonal upon T-cell receptor gamma gene rearrangement analysis (Supplementary Fig. S3), confirming that the mutations underlying clonal hematopoiesis had occurred in a bone marrow stem or progenitor cell before T-cell lineage commitment. All three patients progressed after first-line chemotherapy, as opposed to 11/35 (31%; Fisher exact test \( P \) value 0.043) evaluable patients with absent or nonextensive clonal hematopoiesis in the tumor tissue, who had similar clinical characteristics and received a no less intense first-line therapy (Table 2).

**DISCUSSION**

Here, we provided an initial characterization, largely by WES, of clonal hematopoiesis prevalence and histogenetic distribution in cHL cases mostly studied at disease onset. Clonal hematopoiesis was readily observed in elderly patients with cHL but could be detected also in younger ones, and an even higher prevalence might emerge upon deeper targeted sequencing. CHIP-associated mutations displayed a diverse distribution pattern through the HRS cell and microenvironmental tissue components, with significant representation in both (case 5, Fig. 1C), in only the microenvironment (case 2, Fig. 1A; case 1, Fig. 2D), or in none of them (case 4, Fig. 1B; and also case 3 with little spreading in reactive tissue cells, Supplementary Fig. S2). Notably, in the three patients with significant tissue involvement by clonal hematopoiesis, who all failed first-line chemotherapy, a large part of the
Figure 2. Trajectories of clonal hematopoiesis in a patient sequentially developing cHL and AML (case 1). A–C, Nodular sclerosis cHL lymph node biopsy immunostained (red labeling) for CD30 shows various HRS cells strongly expressing this cHL diagnostic marker (A). Immunostaining for the B cell–specific transcription factor PAX5 (B) shows nuclear positivity in a multinucleated Reed–Sternberg cell (black arrow) and, to a higher intensity, in sparse bystander B cells (one indicated by the red arrow). In C, CD3 immunostaining highlights the abundant reactive T cells in the microenvironment surrounding HRS cells. D, Spreading of the DNMT3A R882H mutation: (i) through preneoplastic hematopoiesis in the bone marrow and blood, with multilineage myeloid cell, B-cell, and T-cell involvement and then (ii) through the neoplastic tissues of AML and cHL, in the latter involving reactive tissue cells (mostly T cells) but not HRS cells. Also indicated are the genetic lesions leading to the development of the AML clone (NPM1 mutation) and the HRS cell clone (STAT6 and SOCS1 mutations), arising, respectively, from a myeloid progenitor belonging to clonal hematopoiesis and a mature B cell not belonging to clonal hematopoiesis. HSC, hematopoietic stem cell.
DNMT3A mutations were found exclusively in EBV of the tumor cell clone of B-cell lymphomas (10), and those T-cell lymphomas, mutations of are less prevalent in TET2 (Supplementary Discussion). While relatively frequent in somatic mutation burden (known to be low in EBV chL; ref. 15). However, additional investigations are required to determine whether DNMT3A and TET2 mutations may play a tumor-cell intrinsic role in the pathogenesis of some EBV+ Hodgkin (and non-Hodgkin) B-cell lymphomas.

Regarding the TET2 disruptive variant observed in the lymphoid microenvironment of case 5, we note that, although Buscarlet and colleagues showed an exclusion of TET2-inactivating mutations from the mature T-cell compartment in healthy individuals with CHIP (25), in case 5 the TET2 variant was presumably subclonal to (i.e., occurred later than) the DNMT3A mutation concomitantly present in the microenvironment (because the VAFs of these two mutations in whole lymph node sections were, respectively, 22% and 32% in the onset sample, and 38% and 27% in the relapse sample). This latter finding is in keeping with the multipotent involvement (T-cell lineage included) typical of mutant DNMT3A that was also shown by Buscarlet and colleagues (25) and may point to mutant DNMT3A being permissive to propagation of a subsequent TET2 disruptive variant through the T-cell lineage. However, we also note that, in the microdissected tumor microenvironment of case 5, TET2 mutation VAF was not particularly high (8.4%), and hence we cannot formally exclude that it was entirely contributed by non-T cells.

We also show that the tumor clones of multiple lymphoid and myeloid neoplasms developing in the same patient with

### Table 2. Clinicopathologic features of cHL cases stratified by clonal hematopoiesis distribution in the tissue

<table>
<thead>
<tr>
<th>N = 40 patients</th>
<th>Clonal hematopoiesis in cHL tissue</th>
<th>Extensivea (n = 3)</th>
<th>Absent/nonextensive (n = 37)</th>
<th>Pab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>&gt;60 years</td>
<td>1 (33%)</td>
<td>9 (24%)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>&lt;60 years</td>
<td>2 (67%)</td>
<td>28 (76%)</td>
<td></td>
</tr>
<tr>
<td>EBV status</td>
<td>EBV+</td>
<td>1 (33%)</td>
<td>8 (22%)</td>
<td>0.55</td>
</tr>
<tr>
<td></td>
<td>EBV−</td>
<td>2 (67%)</td>
<td>29 (78%)</td>
<td></td>
</tr>
<tr>
<td>Histotype</td>
<td>Nodular sclerosis</td>
<td>1 (33%)</td>
<td>21 (57%)</td>
<td>0.58</td>
</tr>
<tr>
<td></td>
<td>Mixed cellularity</td>
<td>2 (67%)</td>
<td>12 (32%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>0 (0%)</td>
<td>4 (11%)</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td>Early (≤ IIA)</td>
<td>1 (33%)</td>
<td>13 (37%)d</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Advanced (≥ IIB)</td>
<td>2 (67%)</td>
<td>22 (63%)d</td>
<td></td>
</tr>
<tr>
<td>Outcome of first-line therapy*</td>
<td>No progression</td>
<td>0 (0%)</td>
<td>24 (69%)f</td>
<td>0.043</td>
</tr>
<tr>
<td></td>
<td>Progression</td>
<td>3 (100%)</td>
<td>11 (31%)f</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Follow-up in monthsg</td>
<td>0–6–35</td>
<td>64 (median)g</td>
<td>0.034</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0–149 (range)g</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*aExtensive: VAF ≥10%.
*bBy Fisher exact test except for comparison of follow-up where t test was used.
*cNodular sclerosis versus all other subtypes.
*dClinical stage at diagnosis was not available for two patients (UPN26 and UPN40).
*eABVD in all cases, with the following exceptions of little relevance: (i) COPP/ABV in pediatric patient UPN27, not showing clonal hematopoiesis and not progressing after first-line therapy; (ii) COPP without vincristine in elderly patient UPN41/case 3, whose outcome was not evaluable; and (iii) omission of bleomycin in 3/35 patients (UPN13, UPN25/case 4, and UPN30, all without extensive clonal hematopoiesis and not progressing after first-line therapy). COPP/ABV stands for cyclophosphamide, vincristine sulfate, prednisone, procarbazine hydrochloride/doxorubicin hydrochloride, bleomycin, vinblastine sulfate.
*fOutcome was not available for one patient (UPN40) and not evaluable in another patient (UPN41/case 3) who died early due to acute chemotherapy toxicity.
*gFollow-up was not available for one patient (UPN40) and not evaluable in another (UPN41/case 3).
Clonal hematopoiesis do not necessarily derive all from clonal hematopoiesis, even when (as in case 1 here) the specific mutations driving clonal hematopoiesis in that patient can be present in the tumor clone of the cancer histologies in question and even when such mutations extensively spread through the cell-of-origin lineages and the microenvironment of the neoplasms affecting that patient. Thus, clonal hematopoiesis trajectories must be carefully disentangled to correctly interpret the histogenesis and pathogenesis of multiple blood cancers arising in patients with clonal hematopoiesis.

Finally, the observations made on case 1 raise the question as to whether his AML was related or not to the previous therapy for cHL (see also Supplementary Discussion). The AML clone lacked the genetic signature of typical therapy-related cases (i.e., TPS3 or PPM1D mutations; complex karyotype and/or loss of chromosomes 5 or 7; refs. 1, 5, 8, 26) and instead carried an NPM1 mutation with normal karyotype, typical of de novo AML (20). These findings may suggest a derivation of the leukemia from a large, and thus high-risk, preexisting CHIP clone (driven by mutant DNMT3A), similar to another recently described lymphoma patient with massive CHIP (sustained ≥1,450 HRS cells were microdissected as single cells (or, less frequently, as small aggregates of 2–4 cells attached to one another) according to their characteristic cytomorphology and large cell size, and then catapulted into an opaque adhesive cap of a 0.5 mL tube (Zeiss) in groups of 200 to 300 cells per cap. A similar number of non-HRS cells mostly of lymphoid morphology and T-cell immunophenotype (representative example in Fig. 2C; Supplementary Fig. S1) were microdissected from the same sections in areas of 200 to 300 cells and collected in separate caps (some contamination by macrophages, eosinophils, and/or other cell types cannot be excluded, but it would likely have limited relevance, especially in cases showing extensive clonal hematopoiesis with VAF ≥10%). Following DNA extraction using the Gentra Puregene kit (QIAGEN), whole-genome amplification (WGA) was performed in duplicate from both the HRS and the reactive cell sample as described previously (15).

**Targeted Sequencing of Patient Samples**

All DNA samples from the six newly processed cases were subjected to molecularly barcoded targeted sequencing of 43 genes recurrently mutated in myeloid neoplasms (QIAseq Targeted DNA Custom Panel–CDHS-136402-1040-Qiagen; Supplementary Table S1A), using 40 to 80 ng of input DNA. In addition, the microdissected HRS and reactive cell WGA DNA (250 ng) of case 1 was subjected to molecularly barcoded targeted sequencing of six JAK–STAT pathway genes recurrently mutated in cHL (QIAseq Targeted DNA Custom Panel–CDHS-16895Z-163-Qiagen; Supplementary Table S1B). Libraries were generated according to the manufacturer’s instructions and sequenced on an Illumina MiSeq instrument for 2 × 151 cycles, using MiSeq Reagent Kit v2 or v3. The mean unique depth of coverage was 2,856x for the myeloid gene panel and 1,716x for the JAK–STAT pathway gene panel.

**Bioinformatics Analysis of Targeted Sequencing Data**

Bioinformatics mapping and variant calling of targeted sequencing data [European Nucleotide Archive (ENA) accession number PRJEB42867] was performed with QIAGEN smCounter algorithm v1 or v2 with default settings (27), and variant annotation was performed with Illumina Variant Studio 3.0. Sequencing variants were then subjected to the further following filters and retained only if: (i) variants were predicted to change the gene coding sequence or involved the conserved splice-site (i.e., the four nucleotides surrounding the exon–intron junction); (ii) variants were not present in the Exome Aggregation Consortium (ExAC) database of normal individuals with a population frequency ≥1% (as provided by Illumina Variant Studio 3.0); (iii) variants were present at an allele frequency ≥2%; and (iv) indels were not located in homopolymeric stretches of five nucleotides or longer. In addition, variants called in HRS and reactive lymphoid cell WGA DNA had to be called in both WGA replicates and their mean weighted VAF (reported in Table 1) had to be ≥2%. The SOCS3 disruptive mutation P83AF6X25 (a frameshift deletion of 26 nucleotides) was called in only one of the WGA HRS cell duplicates (VAF 98.6%; 72 unique supporting reads) due to poor coverage of this guanine-cytosine-rich gene in the other duplicate; in the latter, however, visual inspection of the BAM file showed...
21/25 mutant raw reads, and the deletion was confirmed by standard Sanger sequencing of the same WGA DNA (cycling conditions and primers available upon request).

WES Analysis of Clonal Hematopoiesis in a Previous cHL Patient Cohort

We also analyzed our WES data from non-HRS cells of 34 cHL cases that we previously used as a matched counterpart to call somatic mutations in HRS cells of this malignancy (ref. 15; ENA accession number PRJEB25980). DNA from microdissected HRS and reactive cells had been subjected to duplicate WGA and independent WES of the duplicates (referred to as T1-T2 and N1-N2, respectively); furthermore, in most cases (26/34) unamplified genomic DNA from whole blood was also subjected to WES (15). Variant call rate coverage was 157x for the 26 blood leukocyte samples and 149X for the 8 microdissected reactive sample pairs. Bioinformatics analysis focused on a target region of interest represented by 35 genes associated with age-related clonal hematopoiesis as defined by Tuval and Shlush (ref. 9 and Table 1 therein), whose genomic coordinates were retrieved from the NCBI Reference Sequence Database on human genome GRCh37.

Bioinformatics Reanalysis of WES Data

For each sample subjected to WES, the .mpileup file was generated by means of the SAMtools v.1.4 command mpileup with default parameters except disabling the base alignment quality computation as recommended (28) for the subsequent Varscan2 variant calling; see further below) and increasing the minimum mapping quality from 0 to 1 while allowing a maximum depth of 1 billion (instead of 8,000) reads. We then called single-nucleotide variants and indels separately for each sample through Varscan2 (version 2.4.3) command mpileup2snp and mpileup2indel, respectively, using default settings (except that the minimum coverage depth to make a call was increased from 8 to 10, and the P-value threshold was changed from 0.00 to 0.05). Variant mean unique obtained by the bam-read count utility of Varscan2 with default parameters (except raising the minimum base quality from 0 to 20 in all supporting reads). Variants had then to pass Varscan2 sift filter with default setting (except the minimum number of variant-supporting reads was changed from 4 to 2, and the minimum variant allele frequency was changed from 5% to 1%); we also retained variants with supporting reads that were nevertheless flagged as “NoReadCounts” by the sift filter (this is a known bug of Varscan2). Moreover, regarding WGA samples, variants had to be called in both duplicates to efficiently control for false positives potentially introduced by the WGA step as described previously (15). Annotation of the variants was performed by both SNPEff (version n. 41/c) and wAnnovar (29), referring to the following data-sets: 1000G: 2015 aug; ExAC: exac03; dbSNP: avsnp147; cosmic81; clinvar: 20170501; and gnomAD: gnomAD_exome and gnomAD_genome (v.2). We then excluded variants with a gnomAD_AF<0.1%.

Acknowledgments

This work was supported by a grant on cHL to E. Tiacci from AIRC (IG 2019, ID. 23732), a grant on AML to B. Falini from AIRC (IG 2019 number 23604), a grant on AML to B. Falini from ERC (Advanced Grant 2016 number 740230), the Leopold Gruffuel prize from ARC (to B. Falini), and a grant on cHL to G. Schiavoni from the Department of Medicine, University of Perugia (Ricerca di Base 2017–2019).

Received November 10, 2020; revised January 14, 2021; accepted March 2, 2021; published first April 10, 2021.

REFERENCES


Authors’ Disclosures

M.P. Martelli reports personal fees from AbbVie, Amgen, Pfizer, Jazz Pharmaceuticals, Novartis, and Janssen outside the submitted work. No disclosures were reported by the other authors.

Authors’ Contributions

A. Venanzi: Conceptualization, data curation, formal analysis, methodology, writing–original draft, writing–review and editing.
A. Marra: Conceptualization, data curation, formal analysis, methodology, writing–original draft, writing–review and editing.
G. Schiavoni: Data curation, formal analysis, funding acquisition, methodology.


Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma

Alessandra Venanzi, Andrea Marra, Gianluca Schiavoni, et al.


**Updated version**
Access the most recent version of this article at:
doi: 10.1158/2643-3230.BCD-20-0203

**Supplementary Material**
Access the most recent supplemental material at:
http://bloodcancerdiscov.aacrjournals.org/content/suppl/2021/03/04/2643-3230.BCD-20-0203.DC1

**Cited articles**
This article cites 29 articles, 9 of which you can access for free at:
http://bloodcancerdiscov.aacrjournals.org/content/2/3/216.full#ref-list-1

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, use this link
http://bloodcancerdiscov.aacrjournals.org/content/2/3/216.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.